November 4, 2015 SOURCE: REGEN BIOPHARMA INC.
Regen BioPharma Files Patent Application on Personalized Checkpoint Inhibitor Cancer Immunotherapy. Company Intends to Utilize NR2F6 Gene-Silenced Immune Cells to Amplify Body’s Own Anti-Tumor Defenses.
October 13, 2015 SOURCE: REGEN BIOPHARMA INC.
Regen BioPharma Inc. Announces Appointment of Dr. Harry Lander as President. Dr. Lander was the former assistant provost of Weill Cornell Medical College at Cornell University and research chief at Sidra Medical and Research Center (Qatar)
September 29, 2015 SOURCE: REGEN BIOPHARMA INC.
Regen BioPharma, Inc. Cancer Stem Cell Gene Target Shown to be a Key Mediator of Cancer Immune Surveillance by Independent Researchers
September 25, 2015 SOURCE: REGEN BIOPHARMA INC.
Regen BioPharma, Inc. Announces Positive Results from GLP Safety Study for HemaXellerate
September 23, 2015 SOURCE: REGEN BIOPHARMA INC.
Regen Biopharma Inc. Initiates Small Molecule Hit Validation Study on Cancer Stem Cell Target Gene
September 16, 2015 SOURCE: REGEN BIOPHARMA INC.
Regen BioPharma, Inc. Files Utility Patent Application on Immune Based Therapy for Cancer
September 28, 2015 SOURCE: REGEN BIOPHARMA INC.
Regen BioPharma, Inc. Director of Molecular Therapeutics to Speak at Stem Cell Conference Regarding Leukemia Research Being Conducted by the Company
August 31, 2015 SOURCE: REGEN BIOPHARMA INC.
Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer
August 24, 2015 SOURCE: REGEN BIOPHARMA INC.
Regen BioPharma, Inc. BORIS Gene Silencing Technology Successfully Utilized by Independent Researchers to Kill Breast Cancer and Colon Cancer Stem Cells
August 10, 2015 SOURCE: REGEN BIOPHARMA INC.
Regen BioPharma Inc. Progresses in FDA Responses to dCellVax Clinical Trial Questions